A Cure For Cancer? Look At This Biotech ETF (XBI)

biotechTom Dyson from istockanalyst.com reports that “Since 1983, the biotech sector as a whole has seen four triple-digit rallies… and even one quadruple-digit rally. That’s just for the whole sector. Some individual stocks went much higher. You see, investors love the promise of cancer cures and miracle drugs… so it’s easy for them to justify piling onto a rally.”

“That’s why you don’t even need a bull market to make huge gains in biotech. In any given year, a few tiny biotech companies hit it big with new procedures or drugs. So if you’re hunting for giant winners that rise 300%… or even 600% in a year, you must keep an eye on this space,” Reports Tom Dyson.

The ETF had declined with the rest of the market earlier this year but, has since rebounded.  This Biotech ETF (XBI) offers a wide range of biotechnology companies within S&P Biotechnology Select Industry index.  I have included a list of the top 10 holdings in the ETF.

Company Symbol % Assets
Amgen Inc. AMGN 4.45
BioMarin Pharmaceutical Inc. BMRN 4.71
Celera Corporation CRA 4.48
Cephalon, Inc. CEPH 4.41
Cubist Pharmaceuticals, Inc. CBST 4.63
Gilead Sciences, Inc. GILD 4.61
Isis Pharmaceuticals, Inc. ISIS 5.18
Martek Biosciences Corporation MATK 4.74
United Therapeutics Corporation UTHR 4.52
Vertex Pharmaceuticals Incorpor VRTX 4.77

Full Story:  HERE

We ran this BIOTECH ETF through the market club software and found the following results from their chart analysis program:

Smart Scan Chart Analysis shows the current uptrend is at a crossroads and has possibly ended. Look for choppy trading action in the nearterm Very Weak Uptrend with very tight stops.

Based on a pre-defined weighted trend formula for chart analysis, XBI scored +60 on a scale from -100 (strong downtrend) to +100 (strong uptrend):

-10 Last Hour Close Below 5 hour Moving Average
+15 New 3 Day High on Thursday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, Week Ending June 6th
-30 New 3 Month Low in March
+60 Total Score

Leave a Reply

Your email address will not be published. Required fields are marked *